Evidence map›Paper›PMID 34288948›Full record

ArticlePloS one2021

Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease.

Bader Alsuwailem, Abdelrahman Zamzam, Muzammil H Syed, Elisa Greco, Mark Wheatcroft, Charles de Mestral, Mohammed Al-Omran, John Harlock, John Eikelboom, Krishna K Singh and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Bader AlsuwailemDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Abdelrahman ZamzamDivision of Vascular Surgery, St. Michael's Hospital, Toronto, ON, Canada.
Muzammil H SyedDivision of Vascular Surgery, St. Michael's Hospital, Toronto, ON, Canada.
Elisa GrecoDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Mark WheatcroftDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Charles de MestralDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Mohammed Al-OmranDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
John HarlockDepartment of Surgery, Hamilton General Hospital, Hamilton, Canada.
John EikelboomPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Krishna K SinghDepartment of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Rawand AbdinDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Mohammad QaduraDepartment of Surgery, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0893-9920
St. Michael's Hospital · CAHamilton General Hospital · CAMcMaster University · CAPopulation Health Research Institute · CAUniversity of Toronto · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N-terminal pro B-type natriuretic peptide (NT-proBNP), a cardiac disease biomarker, has been demonstrated to be a strong independent predictor of cardiovascular events in patients without heart failure. Patients with peripheral arterial disease (PAD) are at high risk of cardiovascular events and death. In this study, we investigated levels of NT-proBNP in patients with PAD compared to non-PAD controls. A total of 355 patients were recruited from outpatient clinics at a tertiary care hospital network. Plasma NT-proBNP levels were quantified using protein multiplex. There were 279 patients with both clinical and diagnostic features of PAD and 76 control patients without PAD (non-PAD cohort). Compared with non-PAD patients, median (IQR) NT-proBNP levels in PAD patients were significantly higher (225 ng/L (120-363) vs 285 ng/L (188-425), p- value = 0.001, respectively). Regression analysis demonstrated that NT-proBNP remained significantly higher in patients with PAD relative to non-PAD despite adjusting for age, sex, hypercholesterolemia, smoking and hypertension [odds ratio = 1.28 (1.07-1.54), p-value <0.05]. Subgroup analysis showed elevated NT-proBNP levels in patients with PAD regardless of prior history of CHF, CAD, diabetes and hypercholesteremia (p-value <0.05). Finally, spearmen's correlation analysis demonstrated a negative correlation between NT-proBNP and ABI (ρ = -0.242; p-value < 0.001). In conclusion, our data shows that patients with PAD in an ambulatory care setting have elevated levels of NT-proBNP compared to non-PAD patients in the absence of cardiac symptoms.

Indexed as

AgedComorbidityDiabetes MellitusFemaleHeart DiseasesHumansHypercholesterolemiaHypertensionMaleMiddle AgedNatriuretic Peptide, BrainOutpatient Clinics, HospitalOutpatientsPeptide FragmentsPeripheral Arterial DiseaseSmokingNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID34288948
PMCPMC8294530
OpenAlexW3183360062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.